Basis For Lamivudine Efficacy

28 July 1996

- Further support for the use of Glaxo Wellcome/BioChem Pharma's Epivir/ 3TC (lamivudine) as a basis for combination therapy was the finding that the compound increases the fidelity of HIV reverse transcriptase. Lamivudine achieves this by stimulating a mutation (M184V), which hinders the development of other resistance mutations which might compromise sensitivity to other reverse transcriptase inhibitors. Mark Wainberg of McGill University in Montreal, who presented the study, noted that treating patients early with lamivudine might create a pool of virus with less mutagenic RT, which could enhance prognosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight